Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (BSI, CDI, cUTI, cIAI), By Pathogen (E. coli, P. Aeruginosa, K. Pneumoniae), By Drug Class, and Segment Forecasts, 2018 - 2025

Published: Dec, 2018 | Pages: 120 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)

The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.

Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don't find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.

Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.

Further key findings from the report suggest:

• In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains

• The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period

• Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost

• On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region

• Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.

 Table of Contents

Chapter 1 Report Scope
                 1.1 Segment Market Scope
                 1.2 Regional Scope
                 1.3 Estimates & Forecast Timeline
Chapter 2 Research Methodology
                 2.1 Model Details
                     2.1.1 Regression and variable analysis
                 2.2 Information Procurement
                     2.2.1 List of secondary sources
                 2.3 List of Primary Sources
                 2.4 Purchased database:
                 2.5 GVR's internal database
                 2.6 Primary interview breakup
                     2.6.1 Data for primary interviews, by sources
                     2.6.2 Data for primary interviews, by region
Chapter 3 Report Objectives
                 3.1 Objectives
Chapter 4 Executive Summary
                 4.1 Market Summary
                 4.2 Porter's five forces analysis
Chapter 5 Market Definitions
Chapter 6 Industry Outlook
                 6.1 Business Segment Trend Analysis
                 6.2 Pricing Analysis
                 6.3 Market Variable Analysis
                     6.3.1 Market Driver Analysis
                         6.3.1.1 High burden of antibiotic-resitant pathogens generates demand for new antibiotics
                         6.3.1.2 Increase in global initiatives to control drug-resistance
                     6.3.2 Market Restraints Analysis
                         6.3.2.1 High treatment costs
                 6.4 Business Environment Analysis Tools
                     6.4.1 Antibiotic resistance market - SWOT analysis, by factor (political & legal, economic and technological)
                     6.4.2 Penetration & growth prospect mapping by disease, 2017
Chapter 7 Regulatory Landscape
                 7.1 U.S.
                 7.2 Canada
                 7.3 Europe
                 7.4 Asia Pacific
                 7.5 Latin America
Chapter 8 Competitive & Vendor Landscape
                 8.1 Market Participation Categorization
                     8.1.1 Market leader
                     8.1.2 Innovators
                 8.2 Strategic Initiatives & Outcome Analysis
                 8.3 Company Market Share Analysis
                     8.3.1 Antibiotic resistance company market share analysis, 2014 & 2025
Chapter 9 Antibiotic Resistance Market: Disease Analysis
                 9.1 Disease Type Business Analysis
                     9.1.1 Clostridium difficile infections (CDI)
                         9.1.1.1 CDI market estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.2 Complicated Intra Abdominal Infections (cIAI)
                         9.1.2.1 cIAI market estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.3 Acute bacterial skin and skin structure infections (ABSSSI)
                         9.1.3.1 ABSSSI estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.4 Hospital acquired bacterial pneumonia/ventilator associated bacterial pneumonia (HABP/VABP)
                         9.1.4.1 HABP/VABP estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.5 Community Acquired Bacterial Pneumonia (CABP)
                         9.1.5.1 CABP estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.6 Complicated urinary tract infections (cUTI)
                         9.1.6.1 cUTI estimates and forecasts, 2014 - 2025 (USD Million)
                     9.1.7 Bloodstream Infections (BSI)
                         9.1.7.1 BSI estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 10 Antibiotic Resistance Market: Pathogen Type Analysis
                 10.1 Pathogen Type Business Analysis
                     10.1.1 Acinetobacter baumannii (Carbapenem-Resistant)
                         10.1.1.1 Acinetobacter baumannii market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.2 Staphylococcus Aureus (Methicillin-Resistant)
                         10.1.2.1 Staphylococcus Aureus (Methicillin-Resistant) market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.3 Pseudomonas aeruginosa (Carbapenem-Resistant)
                         10.1.3.1 Pseudomonas aeruginosa market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.4 E. coli/K. pneumoniae (Carbapenem-Resistant)
                         10.1.4.1 E. coli/K. pneumoniae market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.5 Enterococcus faecium (Vancomycin-Resistant)
                         10.1.5.1 Enterococcus faecium market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.6 Streptococcus pneumoniae (Penicillin-Non-Susceptible)
                         10.1.6.1 Streptococcus pneumoniae market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.7 Haemophilus influenzae (Ampicillin-Resistant)
                         10.1.7.1 Haemophilus influenzae market estimates and forecasts, 2014 - 2025 (USD Million)
                     10.1.8 Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
                         10.1.8.1 Clostridium difficile market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 11 Antibiotic Resistance Market: Drug Class Analysis
                 11.1 Drug Class Business Analysis
                     11.1.1 Tetracyclines
                         11.1.1.1 Tetracyclines market estimates and forecasts, 2014 - 2025 (USD Million)
                     11.1.2 Oxazolidinones
                         11.1.2.1 Oxazolidinones market estimates and forecasts, 2014 - 2025 (USD Million)
                     11.1.3 Lipoglycopeptides/glycopeptides
                         11.1.3.1 Lipoglycopeptides/Glycopeptides market estimates and forecasts, 2014 - 2025 (USD Million)
                     11.1.4 Cephalosporins
                         11.1.4.1 Cephalospirins market estimates and forecasts, 2014 - 2025 (USD Million)
                     11.1.5 Combination therapies
                         11.1.5.1 combination therpaies market estimates and forecasts, 2014 - 2025 (USD Million)
                     11.1.6 Others
                         11.1.6.1 Others therpaies market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 12 Antibiotic resistance Market: Regional Analysis
                 12.1 North America
                     12.1.1 North America Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.1.2 U.S.
                         12.1.2.1 U.S. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.1.3 Canada
                         12.1.3.1 Canada Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.2 Europe
                     12.2.1 Europe Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.2 U.K.
                         12.2.2.1 U.K. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.3 Germany
                         12.2.3.1 Germany Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.4 France
                         12.2.4.1 France Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.5 Italy
                         12.2.5.1 Italy Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.6 Spain
                         12.2.6.1 Spain Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.7 Belgium
                         12.2.7.1 Belgium Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.8 Greece
                         12.2.8.1 Greece Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.2.9 Portugal
                         12.2.9.1 Portugal Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.3 Asia Pacific
                     12.3.1 Asia Pacific Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.2 Japan
                         12.3.2.1 Japan Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.3 China
                         12.3.3.1 China Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.4 India
                         12.3.4.1 India Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.5 South Korea
                         12.3.5.1 Korea Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.6 Australia
                         12.3.6.1 Australia Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.7 Hong kong
                         12.3.7.1 Hong Kong Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.8 Singapore
                         12.3.8.1 Singapore Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.3.9 Taiwan
                         12.3.9.1 Taiwan Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.4 Latin america
                     12.4.1 Latin America Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.4.2 Brazil
                         12.4.2.1 Brazil Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.4.3 Mexico
                         12.4.3.1 Mexico Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.4.4 Argentina
                         12.4.4.1 argentina Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                 12.5 Middle east and africa
                     12.5.1 MEA Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.5.2 South Africa
                         12.5.2.1 South Africa Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.5.3 Saudi Arabia
                         12.5.3.1 Saudi Arabia Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.5.4 Turkey
                         12.5.4.1 Turkey Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
                     12.5.5 U.A.E.
                         12.5.5.1 U.A.E. Antibiotic resistance market estimates and forecasts, 2014 - 2025 (USD Million)
Chapter 13 Company Profiles
                 13.1 Key Company Profiled
                     13.1.1 Achaogen, Inc.
                         13.1.1.1 Company overview
                         13.1.1.2 Financial performance
                         13.1.1.3 Product overview
                         13.1.1.4 Regulatory developments
                         13.1.1.5 Product pipeline
                         13.1.1.6 Business strategies
                         13.1.1.7 SWOT analysis
                     13.1.2 Basilea Pharmaceutica Ltd.
                         13.1.2.1 Company Overview
                         13.1.2.2 Financial Performance
                         13.1.2.3 Product Overview
                         13.1.2.4 Regulatory Developments
                         13.1.2.5 Product Pipeline
                         13.1.2.6 Business Strategies
                         13.1.2.7 SWOT Analysis
                     13.1.3 Melinta Therapeutics
                         13.1.3.1 Company Overview
                         13.1.3.2 Financial Performance
                         13.1.3.3 Product Overview
                         13.1.3.4 Regulatory Developments
                         13.1.3.5 Product Pipeline
                         13.1.3.6 Business Strategies
                         13.1.3.7 SWOT Analysis
                     13.1.4 Tetraphase Pharmaceuticals, Inc.
                         13.1.4.1 Company Overview
                         13.1.4.2 Financial Performance
                         13.1.4.3 Product Overview
                         13.1.4.4 Regulatory Developments
                         13.1.4.5 Product pipeline
                         13.1.4.6 Business strategies
                         13.1.4.7 SWOT analysis
                     13.1.5 Theravance Biopharma, Inc.
                         13.1.5.1 Company overview
                         13.1.5.2 Financial performance
                         13.1.5.3 Product overview
                         13.1.5.4 Regulatory Developments
                         13.1.5.5 Product pipeline
                         13.1.5.6 Business strategies
                         13.1.5.7 Swot analysis
                     13.1.6 Wockhardt therapeutics
                         13.1.6.1 Company overview
                         13.1.6.2 Product overview
                         13.1.6.3 Clinical trials
                         13.1.6.4 SWOT analysis
                     13.1.7 Entasis Therapeutics
                         13.1.7.1 Company overview
                         13.1.7.2 Product overview
                         13.1.7.3 Clinical trials
                         13.1.7.4 SWOT analysis
                     13.1.8 PARATEK therapeutics
                         13.1.8.1 Company overview
                         13.1.8.2 Product overview
                         13.1.8.3 Clinical trials
                         13.1.8.4 SWOT analysis
                     13.1.9 Seres Therapeutics, Inc.
                         13.1.9.1 Company overview
                         13.1.9.2 Product overview
                         13.1.9.3 Clinical trials
                         13.1.9.4 SWOT analysis
Chapter 14 Pipeline Analysis
                 14.1 Clinical pipeline activity
                 14.2 Promising therapies - By Disease
                     14.2.1 ABSSSI
                     14.2.2 Pneumonia (CABP/HABP/VABP)
                     14.2.3 CABP
                     14.2.4 HABP/VABP
                     14.2.5 cIAI
                     14.2.6 cUTI 
                 14.3 Promising therapies - By pathogen
                     14.3.1 Staphlococcus Aureus (Methicillin resistant)
                     14.3.2 Enterobacteriaceae (Carbapenem resistant)
                 14.4 Potential breakthrough drugs

List of Tables

Table.1 List of Abbreviations
Table.2 Country share estimation

List of Figures

Fig. 1 Market segmentation
Fig. 2 Market research process
Fig. 3 Value chain-based sizing & forecasting
Fig. 4 QFD modelling for market share assessment
Fig. 5 Information procurement
Fig. 6 Primary interviews, by sources
Fig. 7 Primary interviews, by region
Fig. 8 Porter's Five Forces Analysis
Fig. 9 Antibiotic resistance market revenues, 2017, (USD Millions)
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraints relevance analysis (Current & future impact)
Fig. 13 Antibiotic resistance - SWOT analysis, by factor (political & legal, economic and technological)
Fig. 14 Penetration &growth prospect mapping by disease, 2017
Fig. 15 Strategy framework analysis, 2017
Fig. 16 Antibiotic resistance company market share(%), 2017
Fig. 17 Antibiotic resistance market disease outlook: Key takeaways
Fig. 18 Antibiotic resistance market: Disease movement analysis
Fig. 19 Global CDI market, 2014 - 2025 (USD Million)
Fig. 20 Global cIAI market, 2014 - 2025 (USD Million)
Fig. 21 Global ABSSSI market, 2014 - 2025 (USD Million)
Fig. 22 Global HABP/VABP market, 2014 - 2025 (USD Million)
Fig. 23 Global CABP market, 2014 - 2025 (USD Million)
Fig. 24 Global cUTI market, 2014 - 2025 (USD Million)
Fig. 25 Antibiotic resistance market, Pathogen type: Key takeaways
Fig. 26 Antibiotic resistance market: Pathogen movement analysis
Fig. 27 Global A. baumannii surgery market, 2014 - 2025 (USD Million)
Fig. 28 Global S aureus market, 2014 - 2025 (USD Million)
Fig. 29 Global P. aeruginosa market, 2014 - 2025 (USD Million)
Fig. 30 Global E. coli/K. pneumoniae market, 2014 - 2025 (USD Million)
Fig. 31 Global Enterococcus faecium market, 2014 - 2025 (USD Million)
Fig. 32 Global Streptococcus pneumoniae market, 2014 - 2025 (USD Million)
Fig. 33 Global H. influenza market, 2014 - 2025 (USD Million)
Fig. 34 Global C. difficile market, 2014 - 2025 (USD Million)
Fig. 35 Antibiotic resistance market end use outlook: Key takeaways
Fig. 36 Antibiotic resistance market: End use movement analysis
Fig. 37 Global Tetracyclines market, 2014 - 2025 (USD Million)
Fig. 38 Global Oxazolidinones market, 2014 - 2025 (USD Million)
Fig. 39 Global lipoglycopeptides/glycopeptides market, 2014 - 2025 (USD Million)
Fig. 40 Global Cephalosporins market, 2014 - 2025 (USD Million)
Fig. 41 Global combination therapy market, 2014 - 2025 (USD Million)
Fig. 42 Global other therapy market, 2014 - 2025 (USD Million)
Fig. 43 Regional market place: Key takeaways
Fig. 44 Regional outlook, 2014 - 2025 (USD Million)
Fig. 45 North America Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 46 U.S. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 47 Canada Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 48 Europe Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 49 U.K. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 50 Germany Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 51 France Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 52 Italy Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 53 Spain Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 54 Belgium Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 55 Greece Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 56 Portugal Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 57 Asia Pacific Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 58 Japan Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 59 China Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 60 India Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 61 Korea Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 62 Australia Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 63 Hong Kong Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 64 Singapore Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 65 Taiwan Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 66 Latin America Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 67 Brazil Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 68 Mexico Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 69 Argentina Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 70 MEA Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 71 South Africa Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 72 Saudi Arabia Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 73 Turkey Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 74 U.A.E. Antibiotic resistance market, 2014 - 2025 (USD Million)
Fig. 75 Achaogen, Inc. - SWOT analysis
Fig. 76 Basilea Pharmaceutica - SWOT analysis
Fig. 77 Melinta - SWOT analysis
Fig. 78 Tetraphase Pharmaceuticals - SWOT analysis
Fig. 79 Theravance Biopharma - SWOT analysis
Fig. 80 Nabriva Therapeutics - SWOT analysis
Fig. 81 Nabriva Therapeutics - SWOT analysis
Fig. 82 Paratek Therapeutics - SWOT analysis
Fig. 83 Seres Therapeutics, Inc. - SWOT analysis
Fig. 84 Pipeline Therapies
Fig. 85 Promising Therapies